Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indication · Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]
Matthew Fyfe joins as Senior Vice President of Therapeutics Beth Thomas promoted to Vice President of Medicinal Chemistry 10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe […]
Early data read out indicates a successful LPS human challenge trial Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full […]
